Cargando…

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

BACKGROUND: It remains unclear what the antiviral therapy affects disease-free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jian-Lin, Lin, Xiao-Jun, Zhou, Qian, Shi, Ming, Li, Sheng-Ping, Lao, Xiang-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799530/
https://www.ncbi.nlm.nih.gov/pubmed/26992891
http://dx.doi.org/10.1186/s40880-016-0089-z
_version_ 1782422365023502336
author Chen, Jian-Lin
Lin, Xiao-Jun
Zhou, Qian
Shi, Ming
Li, Sheng-Ping
Lao, Xiang-Ming
author_facet Chen, Jian-Lin
Lin, Xiao-Jun
Zhou, Qian
Shi, Ming
Li, Sheng-Ping
Lao, Xiang-Ming
author_sort Chen, Jian-Lin
collection PubMed
description BACKGROUND: It remains unclear what the antiviral therapy affects disease-free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of antiviral treatment with DFS and OS based on the stratification of baseline HBV DNA load in early-stage (stages I and II) HCC patients. METHODS: We included 445 patients with early-stage HBV-related HCC who underwent curative resection, and then classified them into four subgroups based on baseline HBV DNA load and antiviral therapy stratification. The Kaplan–Meier and Cox regression analyses were performed to determine the association of clinical characteristics with survival. RESULTS: The median follow-up period was 74 months. For all patients, cumulative OS rates in the antiviral group were significantly higher than those in the non-antiviral group (log-rank test, P = 0.023), whereas no significant differences in DFS rates were observed. High baseline HBV DNA level was a risk factor associated with short DFS and OS in all patients. In patients with baseline HBV DNA levels ≥2000 IU/mL, antiviral treatment was significantly associated with prolonged DFS and OS (log-rank test, P = 0.041 and 0.001, respectively). In patients with HBV DNA levels <2000 IU/mL or undetectable, antiviral treatment did not show a significant benefit in prolonging DFS and OS. CONCLUSIONS: High baseline HBV DNA levels are associated with poor prognosis in the patients with early-stage HCC, and the antiviral treatment could generate survival benefits for the patients. Therefore, antiviral treatment should be given for these patients. However, the effect of antiviral treatment on the patients with low viral load remains unclear, and further investigation is warranted.
format Online
Article
Text
id pubmed-4799530
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47995302016-03-21 Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection Chen, Jian-Lin Lin, Xiao-Jun Zhou, Qian Shi, Ming Li, Sheng-Ping Lao, Xiang-Ming Chin J Cancer Original Article BACKGROUND: It remains unclear what the antiviral therapy affects disease-free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of antiviral treatment with DFS and OS based on the stratification of baseline HBV DNA load in early-stage (stages I and II) HCC patients. METHODS: We included 445 patients with early-stage HBV-related HCC who underwent curative resection, and then classified them into four subgroups based on baseline HBV DNA load and antiviral therapy stratification. The Kaplan–Meier and Cox regression analyses were performed to determine the association of clinical characteristics with survival. RESULTS: The median follow-up period was 74 months. For all patients, cumulative OS rates in the antiviral group were significantly higher than those in the non-antiviral group (log-rank test, P = 0.023), whereas no significant differences in DFS rates were observed. High baseline HBV DNA level was a risk factor associated with short DFS and OS in all patients. In patients with baseline HBV DNA levels ≥2000 IU/mL, antiviral treatment was significantly associated with prolonged DFS and OS (log-rank test, P = 0.041 and 0.001, respectively). In patients with HBV DNA levels <2000 IU/mL or undetectable, antiviral treatment did not show a significant benefit in prolonging DFS and OS. CONCLUSIONS: High baseline HBV DNA levels are associated with poor prognosis in the patients with early-stage HCC, and the antiviral treatment could generate survival benefits for the patients. Therefore, antiviral treatment should be given for these patients. However, the effect of antiviral treatment on the patients with low viral load remains unclear, and further investigation is warranted. BioMed Central 2016-03-18 /pmc/articles/PMC4799530/ /pubmed/26992891 http://dx.doi.org/10.1186/s40880-016-0089-z Text en © Chen et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Chen, Jian-Lin
Lin, Xiao-Jun
Zhou, Qian
Shi, Ming
Li, Sheng-Ping
Lao, Xiang-Ming
Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title_full Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title_fullStr Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title_full_unstemmed Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title_short Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
title_sort association of hbv dna replication with antiviral treatment outcomes in the patients with early-stage hbv-related hepatocellular carcinoma undergoing curative resection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799530/
https://www.ncbi.nlm.nih.gov/pubmed/26992891
http://dx.doi.org/10.1186/s40880-016-0089-z
work_keys_str_mv AT chenjianlin associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection
AT linxiaojun associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection
AT zhouqian associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection
AT shiming associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection
AT lishengping associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection
AT laoxiangming associationofhbvdnareplicationwithantiviraltreatmentoutcomesinthepatientswithearlystagehbvrelatedhepatocellularcarcinomaundergoingcurativeresection